Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 11/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 16/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ARNT | P27540 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18036730 | 1.00 | VEGFA (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL18036831 | 0.89 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL21005044 | 0.89 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL29426414 | 0.88 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL16560911 | 0.88 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL16560855 | 0.88 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL16560907 | 0.88 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL18036826 | 0.87 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL16560860 | 0.87 | EPAS1 (1.00) | VEGFAEPAS1CYP2C9ARNTCYP2C19 | |
| SCHEMBL18036933 | 0.85 | VEGFA (0.80) | VEGFAEPAS1CYP2C9ARNTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | PELOTON THERAPEUTICS INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017053192-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016168510-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| WO-2015035223-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | VEGFA 45/4885EPAS1 16/4885CYP2C9 4763/4885 |
| US-20210222257-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | VEGFA 641/4885EPAS1 14/4885CYP2C9 4502/4885 |
| US-20210015764-A1 | METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2- ALPHA | HIF1AN, EGLN2, EGLN3 | VEGFA 2429/4885EPAS1 30/4885CYP2C9 3569/4885 |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | VEGFA 21/4885EPAS1 9/4885CYP2C9 1939/4885 |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | VEGFA 21/4885EPAS1 9/4885CYP2C9 1939/4885 |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | VEGFA 21/4885EPAS1 9/4885CYP2C9 1939/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | VEGFA 21/4885EPAS1 9/4885CYP2C9 1939/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | VEGFA 21/4885EPAS1 9/4885CYP2C9 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.